Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cytohesin-1 (CYTH1) is a cytoplasmic guanine nucleotide exchange factor primarily for the ADP-ribosylation factor (ARF) family of small GTPases, playing a central role in regulating membrane trafficking and integrin-mediated cell adhesion, especially in immune cells such as lymphocytes and natural killer cells. Structurally, CYTH1 includes an N-terminal coiled-coil domain (involved in dimerization and interaction with scaffolding proteins), a central Sec7 domain (conferring GEF activity), and a C-terminal pleckstrin homology (PH) domain (mediating association with membrane phospholipids). CYTH1 is essential for “inside-out” signaling that activates integrins—critical for immune cell motility, adhesion, and phagocytosis. It also participates in protein sorting, vesicle-mediated transport, and cytoskeletal rearrangements orchestrated by ARF GTPases. Genetic studies indicate that loss-of-function mutations can affect cytokinesis or karyokinesis, with some mouse models showing immune and cell biology phenotypes. Currently, CYTH1 itself is not yet a direct therapeutic drug target, but it is integral to pathways relevant for immune cell activation and migration, and interacts with several protein partners that modulate its role in immune signaling. Note: No approved drugs are known to target CYTH1 directly, and it is not classified as a receptor, enzyme, channel, or transporter in major pharmacological databases. Its role is primarily as a signal mediator via activation of ARF GTPases.
Guanine-nucleotide exchange on ARF1, ARF5, and ARF6 (activation of ARF factors through GDP-GTP exchange); Modulation of integrin activation and adhesion signaling
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cytohesin-1 (CYTH1).